Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Background Tumor mutational burden (TMB) measurement is limited by low tumor purity of samples, which can influence prediction of the immunotherapy response, particularly when using whole-exome sequencing-based TMB (wTMB). This issue could be overcome by targeted panel sequencing-based TMB (pTMB) wi...

Full description

Bibliographic Details
Main Authors: Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun, Boram Lee, Tae Hee Hong, Hongui Cha, Joon Ho Shim, Jongsuk Chung, Chung Lee, Yoon-La Choi, Soohyun Hwang, Yoomi Lee, Hyun Ae Jung, Ji-Yeon Kim, Yeon Hee Park
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001199.full

Internet

https://jitc.bmj.com/content/8/2/e001199.full

Similar Items